

News Release

Biofrontera AG hosts conference call on 13 November 2014 to present results of the third quarter 2014

Leverkusen, Germany, 11 November 2014 – Biofrontera AG (FSE/AIM:B8F) will announce Biofrontera Group results for the 1st nine months of the fiscal year on 13 November 2014. The Biofrontera Management will host a conference call to inform about the consolidated financial statements and discuss the recent progress of the Company.

The conference for shareholders and interested investors will start at 9:00 a.m. (MEZ) in German, at 10:30 a.m. (MEZ) in English.

Telephone conference in German:

13 November 2014, 9:00 a.m.

Dial-in number: +49-(0)69 271 340 800

Room number: 73218216#

Telephone conference in English:

13 November 2014, 10:30 a.m.

Dial-in number: +49-(0)69 271 340 801

+44 (0)203 364 5807

Room number: 51595435#

Please dial into the conference 5 minutes earlier to allow a start in time.

Enquiries

Biofrontera AG
Thomas Schaffer +49 (0)214 87632 0

Cortent Kommunikation AG
Volker Siegert +49-69-5770300-11

Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is **Ameluz[®]**, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic

News Release

Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz[®] for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.

In addition, the Company markets the **Belixos[®]** cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.

Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.

www.biofrontera.com

News Release

Enquiries

Biofrontera AG	+49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chief Executive Officer	press@biofrontera.com
Thomas Schaffer , Chief Financial Officer	www.biofrontera.com
Anke zur Mühlen, Corporate Communications	
Brainwell Asset Solutions	+49 (0) 152 08931514
Jürgen Benker	
finnCap (Nomad and Broker)	+44(0) 20 7220 0500
Geoff Nash / Christopher Raggett (Corporate Finance)	
Steven Norcross(Corporate Broking)	
Seton Services Limited (IR)	+44 (0) 20 7603 6797
Toni Vallen	
Gable Communications	+44 (0) 20 7193 7463
John Bick	+44 (0) 7872 061007

Notes to Editors:

Biofrontera AG (AIM/FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is **Ameluz**[®], a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz[®] for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.

In addition, the Company markets the **Belixos**[®] cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.

Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.

www.biofrontera.com

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.